On September 7, Hybio Pharmaceutical (300199.SZ) announced that its wholly-owned subsidiary Gansu Chengji Biopharmaceutical Co., Ltd. has recently received the "Drug Registration Certificate" for Carboprost Tromethamine Injection (Certificate No.: 2026S03186) issued by China's National Medical Products Administration (NMPA), with the drug approval number Guo Yao Zhun Zi H20265776 and specification of 1ml:250μg (calculated as C₂₁H₃₆O₅).
Carboprost Tromethamine Injection is a prostaglandin prescription drug, classified as chemical drug Class 4, mainly used for the treatment of postpartum hemorrhage caused by uterine atony. According to relevant review principles, the drug is deemed to have passed the generic drug quality and efficacy consistency evaluation upon market approval. Postpartum hemorrhage is the leading cause of maternal death worldwide, and carboprost tromethamine, as a first-line drug for treating atonic postpartum hemorrhage, has stable clinical demand.
Hybio Pharmaceutical stated that this certificate enriches the company's product pipeline in the obstetrics and gynecology field, will enhance the company's market competitiveness in this field, and has a positive impact on the company's future operating performance. The company will promptly promote the production and marketing of this product. In recent years, Hybio Pharmaceutical has continued to deepen its presence in peptide drugs while accelerating deployment in popular tracks such as GLP-1. Its liraglutide injection has been approved for marketing in Singapore, and semaglutide injection (for weight loss) has been accepted by CDE for marketing application.

Source: Securities Daily / Hybio Pharmaceutical Announcement | http://m.toutiao.com/group/7682751816521597474/